A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: SHR-9839 ；SHR-A2009|DRUG: SHR-9839 ； SHR-A1921|DRUG: SHR-9839 ； pemetrexed ；carboplatin|DRUG: SHR-9839 ； Almonertinib
Incidence of dose-limiting toxicity (DLT) (phase IB), 21 days after the first dose was administered to each subject，Up to approximately 24 months.|Incidence and severity of adverse events (AE) and serious adverse events (SAE) and laboratory abnormalities (phase IB), Assess safety and tolerability of SHR-A2009 by way of adverse events (CTCAE v5.0), Begin from sign the ICF until the end of the safety follow-up period，Up to approximately 24 months.|Objective Response Rate (ORR) (phase II)., Evaluated using RECIST 1.1, The first treatment lasted until disease progression，Up to approximately 24 months.
Incidence and severity of adverse events (AE) and serious adverse events (SAE) and laboratory abnormalities (phase II), Assess safety and tolerability of SHR-A2009 by way of adverse events (CTCAE v5.0), Begin from sign the ICF until the end of the safety follow-up period，Up to approximately 24 months.
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.